In CABASTY trial presented by Dr. Stephane Oudard, #Cabazitaxel 16 mg/m2 every 2 weeks (CBZ q2w) + G-CSF was compared to CBZ 25 mg/m2 every 3 weeks (CBZ q3w) in older patients with #mCRPC. In this phase III trial, CBZ q2w significantly reduced the occurrence of grade ≥3 neutropenia and/or neutropenic complications with comparable clinical outcomes. CBZ q2w regimen could become a new standard for elderly mCRPC pts.
.png)